Huahai Pharmaceutical: Subsidiary Changxing Pharmaceutical Obtains Drug Registration Certificate for Magnesium Sodium Potassium Sulfate Oral Concentrated Solution

2026-03-12 20:21:06

Huahai Pharmaceutical announced that its controlling subsidiary, Changxing Pharmaceutical, recently received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration for magnesium sulfate, sodium, and potassium oral concentrated solution. The magnesium sulfate, sodium, and potassium oral concentrated solution is suitable for adults and is used for bowel cleansing before procedures requiring intestinal cleaning. It is not for the treatment of constipation. According to Minai Data, the domestic market sales of this drug are projected to be approximately 327 million yuan in the first three quarters of 2025. Changxing Pharmaceutical has already invested about 4.63 million yuan in research and development for this project.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes